Overview of Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Risk Assessments | Mini-Learning

Overview of Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Risk Assessments | Mini-Learning

May 11, 2026 BioData Solutions

BIOANALYTICAL ESSENTIALS | MINI-LEARNING

Overview of Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Risk Assessments

Click the image to view the video

This video provides a regulatory-aligned overview of ADA and NAb risk assessments, outlining key considerations for IND-enabling immunogenicity strategies. It addresses risk stratification, assay readiness, and the integration of clinical and mechanistic factors.

Interested in diving deeper?

TRAINING VIDEO

Common Technical Document Sections for IND and BLA/NDA

Micro-Learning Videos

Immunogenicity Risk Assessment – Main Components | Micro-Learning

Immunogenicity Risk Assessment – Main Components | Micro-Learning

May 7, 2026

Requirements for IND vs NDA/BLA | Micro-Learning

Requirements for IND vs NDA/BLA | Micro-Learning

November 11, 2025

Disease-Specific Matrix Specificity Testing for PK and ADA Methods for Large Molecules | Micro-Learning

Disease-Specific Matrix Specificity Testing for PK and ADA Methods for Large Molecules | Micro-Learning

November 10, 2025

Related Training Videos

Common Technical Document Sections for IND and BLA/NDA | Training Video

October 4, 2025

An Introduction to Developing and Validating Anti-Drug Antibody Assays for Biologics | Training Video

October 3, 2025

An Introduction to Developing and Validating Ligand-Binding PK Assays for Biologics | Training Video

September 29, 2025